Listen " CEO Clifford on how Moximed has kept singularly focused on developing a shock absorber for the knee "
Episode Synopsis
Osteoarthritis isn’t a typical target for startups but Moximed isn’t developing a typical device. In this episode, CEO Anton Clifford will walk us through the biomedical process that led to the decision to build a shock absorber that can stabilized an injured knee. The route been long, winding and has led the team over some bumpy roads but Moximed is poised to deliver on its long-time promise.
At the start,co-hosts Tom Salemi and Chris Newmarker chat with Associate Editor Sean Whooley about Boston Scientific’s recent analyst day, with a tight focus on why Boston Scientific sees opportunity in China when other medical devices are withdrawing.
Notes for this episode
https://www.massdevice.com/boston-scientific-targets-next-level/
https://www.medicaldesignandoutsourcing.com/china-exposure-medtronic-intuitive-henry-schein-align-envista-dentsply-sirona/
https://www.massdevice.com/zimvie-reports-difficult-macroenvironment-q4-miss/
https://www.massdevice.com/category/massdevice-podcast/
Thanks for listening to the DeviceTalks Weekly Podcast
Subscribe to the DeviceTalks Podcast Network on any major podcast player.
More episodes of the podcast DeviceTalks Podcast Network
How Enovis is accelerating orthopedic recovery with bone stimulation and patient-centered innovation
18/11/2025
Noah Medical’s clear vision for pulmonary bronchoscopy; FOMO: The true costs of MedTech tariffs
14/11/2025
Reimagining GI with AI: Olympus’ Blended Intelligence Approach to Burnout Relief & Patient Safety
11/11/2025
Medtronic’s Kowal describes an exciting future and new applications for cardiac pacing devices
07/11/2025
How Abbott is rethinking heart failure management through smarter monitoring and long-term support
27/10/2025
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.